Home Cart Sign in  
Chemical Structure| 1172500-91-2 Chemical Structure| 1172500-91-2

Structure of 1172500-91-2

Chemical Structure| 1172500-91-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1172500-91-2 ]

CAS No. :1172500-91-2
Formula : C11H16ClNO2S
M.W : 261.77
SMILES Code : O=S(C1CCNCC1)(C2=CC=CC=C2)=O.[H]Cl
MDL No. :MFCD03840151
InChI Key :VHOOEJWBCPRXNM-UHFFFAOYSA-N
Pubchem ID :17749803

Safety of [ 1172500-91-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1172500-91-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 16
Num. arom. heavy atoms 6
Fraction Csp3 0.45
Num. rotatable bonds 2
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 70.33
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

54.55 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.09
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.71
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.77
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.49
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.61

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.93
Solubility 0.311 mg/ml ; 0.00119 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.87
Solubility 0.357 mg/ml ; 0.00136 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.54
Solubility 0.0757 mg/ml ; 0.000289 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.41 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.29

Application In Synthesis of [ 1172500-91-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1172500-91-2 ]

[ 1172500-91-2 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 1189852-16-1 ]
  • [ 1172500-91-2 ]
  • [ 1190058-14-0 ]
YieldReaction ConditionsOperation in experiment
73% With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 100.0℃; for 2.0h; A solution of JV-(7-chloro-2-methylpyrazolo[l ,5-alpha]pyrimidin-5-yl)-4-(2- hydroxypropan-2-yl)benzamide (2F, 86 mg, 0.25 mmol), <strong>[1172500-91-2]4-(phenylsulfonyl)piperidine hydrochloride</strong> (145 mg, 0.50 mmol), and JV,jV-diisopropylethylamine (116 mg, 0.90 mmol) in DMF (1.0 mL) was stirred at 100 0C for 2h. After cooling to room temperature, the mixture was diluted with a few drops of DMSO and methanol, and was then purified by preparatory HPLC (40-55% MeCN/H2O gradient + 0.01% TFA). Lyophilization of the combined fractions gave the titled compound as a white solid (97.2 mg, 73%). 1H NMR (DMSO-d6) delta: 10.90 (s, IH), 7.99 (d, J = 8.8 Hz, 2H), 7.89 - 7.95 (m, 2H), 7.78 - 7.85 (m, IH), 7.68 - 7.76 (m, 2H), 7.60 (d, 2H), 7.28 (s, IH), 6.18 (s, IH), 4.53 (d, J = 12.6 Hz, 2H), 3.69 (tt, J = 11.8, 3.7 Hz, IH), 3.00 - 3.11 (m, 2H), 2.37 (s, 3H), 2.04 (d, J = 10.9 Hz, 2H), 1.75 (qd, J = 12.3, 3.8 Hz, 2H), 1.45 (s, 6H); ESI-MS: m/z 534.2 (M+H)+.
  • 2
  • [ 1172500-91-2 ]
  • (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluoro-4-hydroxyphenyl)propanoic acid [ No CAS ]
  • tert-butyl (S)-(3-(3,5-difluoro-4-hydroxyphenyl)-1-oxo-1-(4-(phenylsulfonyl)piperidin-1-yl)propan-2-yl)carbamate [ No CAS ]
YieldReaction ConditionsOperation in experiment
780 mg With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In dichloromethane; N,N-dimethyl-formamide; for 19.0h; A mixture of <strong>[1172500-91-2]4-(phenylsulfonyl)piperidine hydrochloride</strong> (l .Og, 3.8 mmol), (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluoro-4-hydroxyphenyl)propanoic acid (l .lg, 3.5 mmol), DIPEA (1.8 mL, 10.4 mmol), DCM (16 mL) and DMF (4 mL) was treated with HATU (1.59 g, 4.2 mmol). The mixture was stirred for lh then the resulting solution was allowed to stand for 18 h. The mixture was diluted with dichloro methane (30 mL) and washed with saturated sodium hydrogen carbonate (aq.) (20 mL) then saturated brine (2 x 20 mL). The organic phase was dried (Na2S04) and concentrated in vacuo and purified by chromatography on a Si cartridge eluting with 0-20% DCM in ethyl acetate to give Intermediate 41 A (780 mg). LCMS (Method 3): Rt = 1.25 min. m/z 525.3 [M+H]+
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1172500-91-2 ]

Aryls

Chemical Structure| 885274-65-7

A557953 [885274-65-7]

4-(4-(Methylsulfonyl)phenyl)piperidine

Similarity: 0.74

Chemical Structure| 346688-38-8

A161069 [346688-38-8]

4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine

Similarity: 0.71

Chemical Structure| 76697-50-2

A372187 [76697-50-2]

1-Amino-2-(isopropylsulphonyl)benzene

Similarity: 0.69

Chemical Structure| 1263378-01-3

A234856 [1263378-01-3]

N-Methyl-4-(methylsulfonyl)aniline hydrochloride

Similarity: 0.67

Chemical Structure| 31596-87-9

A135433 [31596-87-9]

2-(Ethylsulfonyl)aniline

Similarity: 0.66

Sulfones

Chemical Structure| 885274-65-7

A557953 [885274-65-7]

4-(4-(Methylsulfonyl)phenyl)piperidine

Similarity: 0.74

Chemical Structure| 346688-38-8

A161069 [346688-38-8]

4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine

Similarity: 0.71

Chemical Structure| 76697-50-2

A372187 [76697-50-2]

1-Amino-2-(isopropylsulphonyl)benzene

Similarity: 0.69

Chemical Structure| 1263378-01-3

A234856 [1263378-01-3]

N-Methyl-4-(methylsulfonyl)aniline hydrochloride

Similarity: 0.67

Chemical Structure| 31596-87-9

A135433 [31596-87-9]

2-(Ethylsulfonyl)aniline

Similarity: 0.66

Related Parent Nucleus of
[ 1172500-91-2 ]

Piperidines

Chemical Structure| 885274-65-7

A557953 [885274-65-7]

4-(4-(Methylsulfonyl)phenyl)piperidine

Similarity: 0.74

Chemical Structure| 346688-38-8

A161069 [346688-38-8]

4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine

Similarity: 0.71

Chemical Structure| 290328-55-1

A100876 [290328-55-1]

4-(Methylsulfonyl)piperidine

Similarity: 0.62

Chemical Structure| 7081-40-5

A108606 [7081-40-5]

3-((9H-Thioxanthen-9-yl)methyl)-1-methylpiperidine hydrochloride hydrate

Similarity: 0.56

Chemical Structure| 597563-39-8

A111273 [597563-39-8]

4-((Methylsulfonyl)methyl)piperidine hydrochloride

Similarity: 0.53